Shares of Bristol Myers Squibb Co. BMY slid 1.43% to $57.38 Wednesday, on what proved to be an all-around mixed trading ...

We recently published a list of Dividend Stock Portfolio For Income: Top 10 Stocks to Buy. In this article, we are going to ...

I always find myself rooting not necessarily for the actor who gave the best performance — because, really, who can say which ...

Geron Corporation's stock dropped 50% before its Q4 2024 earnings report, with Rytelo's revenue close to projections but new ...

Approvals last year included rare disease treatments, new oncology drugs, Eli Lilly’s Kisunla, and Mesoblast's Ryoncil.

Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

The FDA accepted a supplemental biologics license application for Opdivo plus Yervoy as a first-line treatment for some adult ...

Healthcare is considered a defensive industry, since good medical care is needed regardless of economic or market conditions.

"The goal is to expand treatment options for HER2-mutant NSCLC, which is currently a challenging and prognostically ...

MONECO Advisors LLC significantly increased its holdings in Bristol-Myers Squibb during the fourth quarter, nearly doubling ...